Sunday, July 3, 2022
News

New approach for devastating brain tumour treatment found during study

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Washington | May 14, 2022 11:53:58 PM IST
There could be a new approach to treating one of the most common and devastating forms of brain cancer in adults, Glioblastoma Multiforme (GBM), the findings from a seven-year research project suggest.

In a peer-reviewed study published by BMC Cancer, scientists from the University of Surrey show that a short chain of amino acids (the HTL-001 peptide) is effective at targeting and inhibiting the function of a family of genes responsible for the growth of GBM - Hox genes. The study was conducted in cell and animal models.

The HTL-001 peptide used in the study has undergone safety testing and is suitable for patient trials. These trials are now being considered in GBM and other cancers.

Hardev Pandha, project lead and Professor of Medical Oncology at the University of Surrey, said:

"People who suffer from Glioblastoma Multiforme have a five per cent survival rate over a five-year period - a figure that has not improved in decades. While we are still early in the process, our seven-year project offers a glimmer of hope for finding a solution to Hox gene dysregulation, which is associated with the growth of GBM and other cancers, and which has proven to be elusive as a target for so many years."

Ironically, Hox genes are responsible for the healthy growth of brain tissue but are ordinarily silenced at birth after vigorous activity in the growing embryo. However, if they are inappropriately 'switched on' again, their activity can lead to the progression of cancer. Hox gene dysregulation has long been recognised in GBM.

The project was carried out in collaboration with the universities of Surrey, Leeds and Texas, and HOX Therapeutics, a University of Surrey start-up company based on the University's Surrey Research Park.

Professor Susan Short, co-author of the study from the University of Leeds, said:

"We desperately need new treatment avenues for these aggressive brain tumours. Targeting developmental genes like the HOX genes that are abnormally switched on in the tumour cells could be a novel and effective way to stop glioblastomas growing and becoming life-threatening."

James Culverwell, CEO of HOX Therapeutics, said, "HOX Therapeutics is excited to be associated with this project and we hope that with our continuing support, this research will eventually lead to novel and effective treatments for both brain and other cancers where HOX gene over-expression is a clear therapeutic target." (ANI)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Doctors' Day: 'Idiot' syndrome haunting ...
Immune cells in brain could become new d...
Headache most reported Covid symptom: St...
Doctors' Day: Mandaviya felicitates docs...
Prepare roadmap for pharmacopoeia sector...
Cancer drug has potential to treat muscu...
More...
 
INDIA WORLD ASIA
Fossil collaborating with Google to make...
Raj Thackeray praises Fadnavis for accep...
PM Modi to participate in 2-day BJP Nati...
No race for CM face, Congress to go for ...
BJP's mega show in Hyderabad, national e...
Study explains scarless skin grafting us...
More...    
 
 Top Stories
Second edition of Champions Boat Le... 
'Can't tell how tough time was', co... 
Fraudster held for duping over 200 ... 
Varun Dhawan: Finding balance betwe... 
Telangana CM KCR launches scathing ... 
Rebel Sena MLAs leave for Mumbai fr... 
AAP alleges govt may charge for bor... 
Organisers nix Day N Vegas, Travis ...